AIMZ Investment Advisors LLC Has $1.90 Million Stock Holdings in Abbott Laboratories (NYSE:ABT)

AIMZ Investment Advisors LLC decreased its position in shares of Abbott Laboratories (NYSE:ABT) by 0.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,781 shares of the healthcare product maker’s stock after selling 99 shares during the period. AIMZ Investment Advisors LLC’s holdings in Abbott Laboratories were worth $1,898,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Mutual Advisors LLC raised its position in Abbott Laboratories by 1.8% during the third quarter. Mutual Advisors LLC now owns 22,231 shares of the healthcare product maker’s stock valued at $2,591,000 after acquiring an additional 386 shares in the last quarter. Pathway Financial Advisers LLC raised its holdings in shares of Abbott Laboratories by 99.9% during the 3rd quarter. Pathway Financial Advisers LLC now owns 2,765 shares of the healthcare product maker’s stock valued at $315,000 after purchasing an additional 1,382 shares in the last quarter. Highline Wealth Partners LLC bought a new stake in Abbott Laboratories in the third quarter worth $37,000. Pinnacle Associates Ltd. increased its position in Abbott Laboratories by 6.4% during the third quarter. Pinnacle Associates Ltd. now owns 102,454 shares of the healthcare product maker’s stock worth $11,277,000 after buying an additional 6,146 shares during the last quarter. Finally, SteelPeak Wealth LLC lifted its position in shares of Abbott Laboratories by 49.9% in the third quarter. SteelPeak Wealth LLC now owns 17,302 shares of the healthcare product maker’s stock worth $1,973,000 after buying an additional 5,756 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In related news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the transaction, the executive vice president now owns 125,697 shares in the company, valued at $16,152,064.50. This represents a 15.90 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of recent analyst reports. Barclays reissued an “overweight” rating and issued a $158.00 price objective (up from $149.00) on shares of Abbott Laboratories in a research note on Monday, January 27th. Wells Fargo & Company boosted their price objective on shares of Abbott Laboratories from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, January 23rd. Stifel Nicolaus lifted their target price on shares of Abbott Laboratories from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Evercore ISI upped their price target on shares of Abbott Laboratories to $136.00 and gave the company a “buy” rating in a report on Thursday, January 2nd. Finally, StockNews.com cut Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $133.06.

Abbott Laboratories Trading Down 0.1 %

Shares of ABT stock opened at $135.89 on Friday. The firm has a fifty day moving average of $122.60 and a 200-day moving average of $117.56. The stock has a market cap of $235.67 billion, a price-to-earnings ratio of 17.76, a P/E/G ratio of 2.52 and a beta of 0.75. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $136.99. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting analysts’ consensus estimates of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm had revenue of $10.97 billion during the quarter, compared to analysts’ expectations of $11.03 billion. During the same quarter last year, the company earned $1.19 earnings per share. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.74%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories’s payout ratio is currently 30.85%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.